Long-term efficacy and safety of questionnaire-based initiation of urgency urinary incontinence treatment

Rachel Hess, Alison J. Huang, Holly E. Richter, Chiara C. Ghetti, Vivian W. Sung, Elizabeth Barrett-Connor, William (Tom) Gregory, Joann V. Pinkerton, Catherine S. Bradley, Stephen R. Kraus, Rebecca G. Rogers, Leslee L. Subak, Karen C. Johnson, Lily A. Arya, Michael Schembri, Jeanette S. Brown

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: The objective of the study was to determine the longer-term efficacy and safety of initiating treatment for urgency-predominant urinary incontinence (UUI) in women diagnosed using a simple questionnaire rather than an extensive evaluation. Study Design: Women completing a 12 week randomized controlled trial of fesoterodine therapy for UUI diagnosed by questionnaire were invited to participate in a 9 month, open-label continuation study. UUI and voiding episodes were collected using voiding diaries. Participant satisfaction was measured by questionnaire. Safety was assessed by the measurement of postvoid residual volume and adverse event monitoring; if necessary, women underwent a specialist evaluation. The longitudinal changes in UUI and voiding episodes were evaluated using linear mixed models adjusting for baseline. Results: Of the 567 women completing the randomized trial, 498 (87.8%) took at least 1 dose of medication during this open-label study. Compared with the baseline visit in the randomized trial, fesoterodine was associated with a reduction in total incontinence episodes per day and urgency incontinence episodes per day at the end of the open-label study (adjusted mean [SE], 4.6 [0.12] to 1.2 [0.13] and 3.9 [0.11] to 0.9 [0.11], respectively, P

Original languageEnglish (US)
JournalAmerican Journal of Obstetrics and Gynecology
Volume209
Issue number3
DOIs
StatePublished - Sep 2013

Fingerprint

Urinary Incontinence
Safety
Residual Volume
Therapeutics
Linear Models
Randomized Controlled Trials
Surveys and Questionnaires
fesoterodine

Keywords

  • primary care
  • treatment
  • urgency urinary incontinence

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Long-term efficacy and safety of questionnaire-based initiation of urgency urinary incontinence treatment. / Hess, Rachel; Huang, Alison J.; Richter, Holly E.; Ghetti, Chiara C.; Sung, Vivian W.; Barrett-Connor, Elizabeth; Gregory, William (Tom); Pinkerton, Joann V.; Bradley, Catherine S.; Kraus, Stephen R.; Rogers, Rebecca G.; Subak, Leslee L.; Johnson, Karen C.; Arya, Lily A.; Schembri, Michael; Brown, Jeanette S.

In: American Journal of Obstetrics and Gynecology, Vol. 209, No. 3, 09.2013.

Research output: Contribution to journalArticle

Hess, R, Huang, AJ, Richter, HE, Ghetti, CC, Sung, VW, Barrett-Connor, E, Gregory, WT, Pinkerton, JV, Bradley, CS, Kraus, SR, Rogers, RG, Subak, LL, Johnson, KC, Arya, LA, Schembri, M & Brown, JS 2013, 'Long-term efficacy and safety of questionnaire-based initiation of urgency urinary incontinence treatment', American Journal of Obstetrics and Gynecology, vol. 209, no. 3. https://doi.org/10.1016/j.ajog.2013.05.008
Hess, Rachel ; Huang, Alison J. ; Richter, Holly E. ; Ghetti, Chiara C. ; Sung, Vivian W. ; Barrett-Connor, Elizabeth ; Gregory, William (Tom) ; Pinkerton, Joann V. ; Bradley, Catherine S. ; Kraus, Stephen R. ; Rogers, Rebecca G. ; Subak, Leslee L. ; Johnson, Karen C. ; Arya, Lily A. ; Schembri, Michael ; Brown, Jeanette S. / Long-term efficacy and safety of questionnaire-based initiation of urgency urinary incontinence treatment. In: American Journal of Obstetrics and Gynecology. 2013 ; Vol. 209, No. 3.
@article{d9711283ee0041aa8cc4d8b1b1fefce3,
title = "Long-term efficacy and safety of questionnaire-based initiation of urgency urinary incontinence treatment",
abstract = "Objective: The objective of the study was to determine the longer-term efficacy and safety of initiating treatment for urgency-predominant urinary incontinence (UUI) in women diagnosed using a simple questionnaire rather than an extensive evaluation. Study Design: Women completing a 12 week randomized controlled trial of fesoterodine therapy for UUI diagnosed by questionnaire were invited to participate in a 9 month, open-label continuation study. UUI and voiding episodes were collected using voiding diaries. Participant satisfaction was measured by questionnaire. Safety was assessed by the measurement of postvoid residual volume and adverse event monitoring; if necessary, women underwent a specialist evaluation. The longitudinal changes in UUI and voiding episodes were evaluated using linear mixed models adjusting for baseline. Results: Of the 567 women completing the randomized trial, 498 (87.8{\%}) took at least 1 dose of medication during this open-label study. Compared with the baseline visit in the randomized trial, fesoterodine was associated with a reduction in total incontinence episodes per day and urgency incontinence episodes per day at the end of the open-label study (adjusted mean [SE], 4.6 [0.12] to 1.2 [0.13] and 3.9 [0.11] to 0.9 [0.11], respectively, P",
keywords = "primary care, treatment, urgency urinary incontinence",
author = "Rachel Hess and Huang, {Alison J.} and Richter, {Holly E.} and Ghetti, {Chiara C.} and Sung, {Vivian W.} and Elizabeth Barrett-Connor and Gregory, {William (Tom)} and Pinkerton, {Joann V.} and Bradley, {Catherine S.} and Kraus, {Stephen R.} and Rogers, {Rebecca G.} and Subak, {Leslee L.} and Johnson, {Karen C.} and Arya, {Lily A.} and Michael Schembri and Brown, {Jeanette S.}",
year = "2013",
month = "9",
doi = "10.1016/j.ajog.2013.05.008",
language = "English (US)",
volume = "209",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Long-term efficacy and safety of questionnaire-based initiation of urgency urinary incontinence treatment

AU - Hess, Rachel

AU - Huang, Alison J.

AU - Richter, Holly E.

AU - Ghetti, Chiara C.

AU - Sung, Vivian W.

AU - Barrett-Connor, Elizabeth

AU - Gregory, William (Tom)

AU - Pinkerton, Joann V.

AU - Bradley, Catherine S.

AU - Kraus, Stephen R.

AU - Rogers, Rebecca G.

AU - Subak, Leslee L.

AU - Johnson, Karen C.

AU - Arya, Lily A.

AU - Schembri, Michael

AU - Brown, Jeanette S.

PY - 2013/9

Y1 - 2013/9

N2 - Objective: The objective of the study was to determine the longer-term efficacy and safety of initiating treatment for urgency-predominant urinary incontinence (UUI) in women diagnosed using a simple questionnaire rather than an extensive evaluation. Study Design: Women completing a 12 week randomized controlled trial of fesoterodine therapy for UUI diagnosed by questionnaire were invited to participate in a 9 month, open-label continuation study. UUI and voiding episodes were collected using voiding diaries. Participant satisfaction was measured by questionnaire. Safety was assessed by the measurement of postvoid residual volume and adverse event monitoring; if necessary, women underwent a specialist evaluation. The longitudinal changes in UUI and voiding episodes were evaluated using linear mixed models adjusting for baseline. Results: Of the 567 women completing the randomized trial, 498 (87.8%) took at least 1 dose of medication during this open-label study. Compared with the baseline visit in the randomized trial, fesoterodine was associated with a reduction in total incontinence episodes per day and urgency incontinence episodes per day at the end of the open-label study (adjusted mean [SE], 4.6 [0.12] to 1.2 [0.13] and 3.9 [0.11] to 0.9 [0.11], respectively, P

AB - Objective: The objective of the study was to determine the longer-term efficacy and safety of initiating treatment for urgency-predominant urinary incontinence (UUI) in women diagnosed using a simple questionnaire rather than an extensive evaluation. Study Design: Women completing a 12 week randomized controlled trial of fesoterodine therapy for UUI diagnosed by questionnaire were invited to participate in a 9 month, open-label continuation study. UUI and voiding episodes were collected using voiding diaries. Participant satisfaction was measured by questionnaire. Safety was assessed by the measurement of postvoid residual volume and adverse event monitoring; if necessary, women underwent a specialist evaluation. The longitudinal changes in UUI and voiding episodes were evaluated using linear mixed models adjusting for baseline. Results: Of the 567 women completing the randomized trial, 498 (87.8%) took at least 1 dose of medication during this open-label study. Compared with the baseline visit in the randomized trial, fesoterodine was associated with a reduction in total incontinence episodes per day and urgency incontinence episodes per day at the end of the open-label study (adjusted mean [SE], 4.6 [0.12] to 1.2 [0.13] and 3.9 [0.11] to 0.9 [0.11], respectively, P

KW - primary care

KW - treatment

KW - urgency urinary incontinence

UR - http://www.scopus.com/inward/record.url?scp=84883144063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883144063&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2013.05.008

DO - 10.1016/j.ajog.2013.05.008

M3 - Article

VL - 209

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -